Current Report Filing (8-k)
September 18 2018 - 9:09AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act
May
31, 2018
Date
of Report (Date of Earliest Event Reported)
Phoenix
Life Sciences International Limited.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-167275
|
|
46-0525378
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
of
Incorporation)
|
|
|
|
Identification
Number)
|
|
|
3000
Lawrence Street
Denver,
CO 80205
1.720.699.7222 or Investor
relations +1.888.717.5655
|
|
|
(Address,
including zip code, and telephone number, including area code,
of
registrant's principal executive offices)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☐ Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
PHOENIX
LIFE SCIENCE INTERNATIONAL LIMITED
Form
8-K
Current
Report
ITEM
5.03
AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN COMPANY
NAME
On
May 31, 2018, the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary
of State of Nevada. As a result of the Amendment, the Company has changed its name with the State of Nevada from Stem Bioscience,
Inc. to Phoenix Life Science International Limited. A copy of the Amendment is filed herewith as Exhibit 3.01.
ITEM
7.01
Regulation FD Disclosure
On
September 18, 2018, the Company’s Board of Directors announced the finalized consolidation activities of Phoenix Life Sciences
International Limited with Stem Bioscience, Inc., Blue Dragon Ventures, and the MediJane Brand, and that the Company’s common
stock would trade publicly under the symbol MJMD. A copy of the press release is attached hereto as Exhibit 99.1. The information
in this Item 7.01 and the exhibit attached hereto are furnished to, but not filed with, the Securities and Exchange Commission.
ITEM
9.01
Financial Statements and Exhibits
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Phoenix
Life Science International Limited
|
Date: September 18, 2018
|
By:
|
/s/
Lewis Humer
|
|
|
Lewis Humer
|
|
|
Chief Executive Officer
|
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Apr 2023 to Apr 2024